RE “The associations between pretreatment neutrophil-to-lymphocyte ratio, sarcopenia and frailty in older patients with head and neck cancer”
Erkan Topkan, Efsun Somay, Sibel Bascil, Ugur Selek

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsInflammatory Biomarkers in Disease Prognosis · Nutrition and Health in Aging · Neutropenia and Cancer Infections
Dear Editor,
We congratulate Meerkerk and colleagues on their investigation of the relationships between pretreatment neutrophil-to-lymphocyte ratio (NLR), sarcopenia, and frailty in older patients with head and neck cancer (HNC)[1]. The authors deserve commendation for defining sarcopenia in accordance with the European Working Group on Sarcopenia in Older People criteria[2], requiring concurrent reductions in skeletal muscle strength and mass—an approach that remains uncommon in oncologic research, where imaging-only surrogates are frequently employed. Notwithstanding this definitional rigor, two aspects warrant further consideration, as they may influence the study's clinical applicability and interpretation.
First, although the authors report significant associations between elevated NLR and frailty[1], the discriminatory performance of NLR is inadequate for screening purposes; with a specificity of only 47 % and an overall accuracy of 61 %, nearly half of non-frail patients would be misclassified as potentially frail[3]. Such performance would substantially increase unnecessary referrals for comprehensive geriatric assessment (GA) in real-world practice, contradicting the stated objective of improving efficiency in resource-limited settings. Screening instruments should therefore be evaluated primarily on clinical utility and operational performance, rather than on statistical association alone. Established tools, such as the G8, demonstrate a more favorable balance of sensitivity and specificity and have undergone prospective validation across diverse oncologic populations[4]. When evaluated against this benchmark, NLR does not confer meaningful incremental value.
Second, the study underscores a persistent conceptual issue in the frailty literature: the tendency to conflate frailty with biological surrogates of inflammation or muscle mass. As demonstrated in the multivariable analyses by Meerkerk and colleagues, comorbidity burden and nutritional impairment largely account for the observed association between NLR and frailty[1]. This finding suggests that NLR may function primarily as a nonspecific marker of global disease severity or catabolic stress, rather than reflecting a frailty-specific biological mechanism. Frailty is a multidimensional functional syndrome characterized by impaired physiologic reserve across multiple systems[5]. Reducing this construct to an inflammatory ratio risks biological oversimplification and interpretive overstatement. This concern is particularly salient given that structured GA domains already capture vulnerability more directly and demonstrate greater prognostic relevance.
In conclusion, although the available data do not support the use of NLR as a reliable frailty screening tool, Meerkerk and colleagues demonstrated that systemic inflammation, sarcopenia, and frailty frequently coexist in older patients with HNC[1]. Future investigations would benefit from moving beyond isolated biomarkers toward integrative, prospectively validated models that preserve the functional and multidimensional nature of frailty.
Authors’ contributions
The author conceptualized the commentary, performed the critical analysis of the published study, and wrote the manuscript.
Ethics approval and consent to participate
Not applicable. This Letter to the Editor does not involve original data collection, human participants, or animal experimentation.
Consent for publication
Not applicable.
Availability of data and materials
Not applicable.
Funding
No specific funding was received for this work.
Declaration of the use of generative AI and AI-assisted technologies in scientific writing and in figures, images, and artwork
Not applicable.
CRediT authorship contribution statement
Erkan Topkan: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Efsun Somay: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Sibel Bascil: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Ugur Selek: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
The author is an Editorial Board Member/Editor-in-Chief/Associate Editor/Guest Editor for [Journal name] and was not involved in the editorial review or the decision to publish this article.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Meerkerk C.D.A.Emmelot-Vonk M.H.Haitjema S.de Bree R.The associations between pretreatment neutrophil-to-lymphocyte ratio, sarcopenia and frailty in older patients with head and neck cancer J Aging Res Lifestyle 14202510002210.1016/j.jarlif.2025.100022 PMC 1271777441424817 · doi ↗ · pubmed ↗
- 2Cruz-Jentoft A.J.Bahat G.Bauer J.Sarcopenia: revised European consensus on definition and diagnosis Age Ageing 48201916313031237210.1093/ageing/afy 169PMC 6322506 · doi ↗ · pubmed ↗
- 3Decoster L.Van Puyvelde K.Mohile S.Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations Ann Oncol 2620152883002493658110.1093/annonc/mdu 210 · doi ↗ · pubmed ↗
- 4Bruijnen C.P.Heijmer A.van Harten-Krouwel D.G.Validation of the G 8 screening tool in older patients with cancer considered for surgical treatment J Geriatr Oncol 1220217937983317280610.1016/j.jgo.2020.10.017 · doi ↗ · pubmed ↗
- 5Zwart A.T.van der Hoorn A.van Ooijen P.M.A.CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer J Cachexia Sarcopenia Muscle 102019106010693113476510.1002/jcsm.12443 PMC 6818448 · doi ↗ · pubmed ↗
